メドトロニック plc

Medtronic plc is the world's largest independent medical device company, founded in 1949 in Dublin, Ireland. Its annual revenue for fiscal year 2025 reached 34.76 billion USD, operating over 80 manufacturing and R&D facilities worldwide and employing more than 95,000 people. Medtronic holds a dominant presence in the home medical device sector, particularly in its diabetes business unit, where the integration of insulin pump systems and continuous glucose monitoring (CGM) generates annual revenue exceeding 2.76 billion USD. The company's MiniMed insulin pump series features advanced hybrid closed-loop algorithms that work in conjunction with CGM sensors, recognized as the gold standard for automated insulin delivery.

Strengths: Unmatched scale as the world's largest pure-play medical device company, coupled with deep R&D capabilities. Leading position in diabetes home care through the MiniMed product ecosystem. Strong regulatory expertise with FDA, CE, and markets worldwide. Robust supply chain with manufacturing redundancy across North America, Europe, and Asia. Accelerating revenue growth driven by over 10 consecutive quarters of corporate growth momentum.
Weaknesses: Diabetes business unit facing intense competition from Dexcom and Insulet in the CGM and patch pump segments. Organizational uncertainty from recent evaluations of spinning off the diabetes business. Legacy product lines in cardiovascular and surgical areas facing margin pressure from emerging companies.